Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement.
- Author:
Yong-Zhi ZHENG
1
;
Shao-Hua LE
1
;
Hao ZHENG
1
;
Xue-Ling HUA
1
;
Zai-Sheng CHEN
1
;
Ling ZHENG
1
;
Cai CHEN
1
;
Mei LI
1
;
Chun-Xia CAI
1
;
Jing-Hui YANG
1
;
Yi-Qiao CHEN
1
;
Qin-Li GAO
1
;
Ying-Ying CHEN
1
;
Jian LI
1
;
Jian-Da HU
2
Author Information
- Publication Type:Journal Article
- MeSH: Child; Child, Preschool; Disease-Free Survival; Female; Gene Rearrangement; Humans; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics*; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics*; Prognosis; Receptors, Cytokine/genetics*; Receptors, Purinergic P2Y/genetics*
- From: Journal of Experimental Hematology 2021;29(2):311-315
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical features and prognostic factors of acute lymphoblastic leukemia (ALL) children with P2RY8-CRLF2 gene rearrangement.
METHODS:A total of 108 children with B-cell ALL (B-ALL) were diagnosed and systematically treated according to Chinese Children's Leukemia Group (CCLG) -ALL 2008 in our hospital from January 2016 to December 2016. The 108 patients were divided into two groups according to the result of mutiplex polymerase chain reaction: group with P2RY8-CRLF2 gene rearrangement and group without P2RY8-CRLF2 gene rearrangement. The ALL children with P2RY8-CRLF2 gene rearrangement were all treated by CCLG-ALL 2008 high-risk group (HR) regimens, and the ALL children in group without P2RY8-CRLF2 gene rearrangement received different intensity chemotherapy according to clinical risk classification.
RESULTS:Five (4 male and 1 female) out of 108 patients with B-ALL had P2RY8-CRLF2 gene rearrangement. In the 5 B-ALL patients with P2RY8-CRLF2 gene rearrangement, the median age of the was 4 (2-6) years old and the median WBC count was 26.2 (2.46-525.1)×10
CONCLUSION:The early treatment response and prognosis of ALL children with P2RY8-CRLF2 gene rearrangement are worse, and more effective protocol is needed for this subtype patients.
